




BIOGENIQ

RESULT FROM OUR RETROSPECTIVE STUDY¹: A PHARMACOGENETIC TEST FOR ADHD CAN PREDICT TREATMENT FAILURE WITH PSYCHOSTIMULANTS

Correlation between genetic alerts* and treatment failure with psychostimulants



All subjects for whom a psychostimulant did not work in a clinical setting had a genetic alert.

*A genetic alert refers to the presence of at least one genetic marker associated with an increased risk of treatment failure or adverse drug reactions.

Prescribe the ADHD Pharma Profile, a saliva test for:

Compatibility and dosage recommendations based on product monographs and guidelines from consortiums of clinical experts.

Biron

Since 2018, BiogeniQ has been part of Biron Health Group.





BIOGENIQ

THE ADHD PHARMA PROFILE

Pharmacodynamic* and
pharmacokinetic genetic testing

ADHD PHARMA PROFILE

Psychostimulants

- Amphetamine (Adderall XR®)
- Dextroamphetamine (Dexedrine®)
- Lisdexamfetamine (Vyvanse®)
- Methylphenidate
(Biphentin®, Concerta®, Ritalin®)

Non-psychostimulants

- Atomoxetine (Strattera®)
- Bupropion (Wellbutrin®, Zyban®)
- Clonidine (Catapres®, Dixarit®)
- Guanfacine (Intuniv XR®)
- Risperidone (Risperdal®)

Brand names are displayed as examples and do not represent an exhaustive list.
This list represents the drugs covered by the ADHD Pharma Profile.

Cost of BiogeniQ Pharma Profiles:

First Pharma Profile:

\$285

Each additional Pharma Profile:

+\$120

Other Pharma Profiles available:

Depression | Antipsychotics | Cancer | Cardio | Pain | Miscellaneous

* Methylphenidate only

1. Pharmacogenetic test for the treatment of ADHD with psychostimulants: retrospective study, BiogeniQ, 2018.